Faecal calprotectin is a very reliable tool to predict and monitor the risk of relapse after therapeutic de-escalation in patients with inflammatory bowel diseases - Microbes, Intestin, Inflammation et Susceptibilité de l'Hôte Accéder directement au contenu
Communication Dans Un Congrès Année : 2018

Faecal calprotectin is a very reliable tool to predict and monitor the risk of relapse after therapeutic de-escalation in patients with inflammatory bowel diseases

Résumé

Background The selection of the best patients who may benefit from therapeutic de-escalation (TDE) and how to monitor them is a concern and a clinical challenge in inflammatory bowel diseases (IBD). The role of faecal calprotectin (Fcal) remains poorly investigated in these situations. We aimed to assess Fcal level before TDE as predictor of clinical relapse and to evaluate serial measurements of Fcal to predict clinical relapse after TDE. Methods From a prospectively maintained database, we enrolled all IBD patients in clinical remission, with Fcal measured within 8 weeks before therapeutic de-escalation. TDE was defined as decrease of dose or increase of interval between two infusions/injections or medication discontinuation or replacement by a medication that is traditionally earlier in a “step-up” approach to IBD management (5-ASA < immunosuppressants < biologics). Clinical relapse was defined as reappearance of clinical manifestations (HBI > 4 or SCCAI > 2 with sub-score > 1 for at least one item among stool frequency and rectal bleeding) leading to therapeutic intensification, hospitalisation or IBD-related surgery.
Fichier non déposé

Dates et versions

hal-02734756 , version 1 (02-06-2020)

Identifiants

  • HAL Id : hal-02734756 , version 1
  • PRODINRA : 448728
  • WOS : 000427318901021

Citer

A. Buisson, W. Y. Mak, M. J. Andersen, D. Lei, S. A. Kahn, et al.. Faecal calprotectin is a very reliable tool to predict and monitor the risk of relapse after therapeutic de-escalation in patients with inflammatory bowel diseases. Congress of ECCO - European Crohn's and Colitis Organisation, 2018, Oxford, United Kingdom. ⟨hal-02734756⟩
20 Consultations
0 Téléchargements

Partager

Gmail Facebook X LinkedIn More